This firm's breakthrough has drawn investments from the biggest names in Big Pharma - With companies like Biogen, Sanofi, and Genentech pouring over $1 billion into it.

Unlock the details of this groundbreaking opportunity here...

Arsani William Biography and Net Worth

Director of Design Therapeutics

Arsani William, M.D. has served as a member of our board of directors since January 2021. Dr. William has served as Managing Partner and Chief Investment Officer of Logos Capital since its founding in 2019. Prior to founding Logos, Dr. Williams served as an investment professional at Farallon Capital Management. Dr. Williams holds an M.D. from Harvard Medical School where he was a Gerald S. Foster Scholar, an MBA from Stanford’s Graduate School of Business, and a BS with Honors in Biology from Stanford University.

How do I contact Arsani William?: The corporate mailing address for Dr. William and other Design Therapeutics executives is 6005 HIDDEN VALLEY ROAD SUITE 110, CARLSBAD CA, 92011. Design Therapeutics can also be reached via phone at 858-293-4900 and via email at [email protected]. Learn More on Arsani William's contact information.
Has Arsani William been buying or selling shares of Design Therapeutics?: Arsani William has not been actively trading shares of Design Therapeutics in the last ninety days. Most recently, on Monday, March 21st, Arsani William bought 25,000 shares of Design Therapeutics stock. The stock was acquired at an average cost of $18.99 per share, with a total value of $474,750.00. Learn More on Arsani William's trading history.
Are insiders buying or selling shares of Design Therapeutics?: In the last year, Design Therapeutics insiders bought shares 4 times. They purchased a total of 59,965 shares worth more than $176,820.38. The most recent insider tranaction occured on March, 25th when Director John P Schmid bought 17,809 shares worth more than $66,605.66. Insiders at Design Therapeutics own 27.8% of the company. Learn More about insider trades at Design Therapeutics.
Information on this page was last updated on 3/25/2024.

Arsani William Insider Trading History at Design Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
3/21/2022	Buy	25,000	$18.99	$474,750.00
8/31/2021	Buy	40,000	$15.45	$618,000.00

Arsani William Buying and Selling Activity at Design Therapeutics

Design Therapeutics Company Overview

Design Therapeutics, Inc. a biopharmaceutical company, researches, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States. The company utilizes its GeneTAC platform to design and develop therapeutic candidates for inherited diseases caused by nucleotide repeat expansion. Its lead product candidates for potentially disease-modifying treatment comprises Friedreich Ataxia, a monogenic, autosomal recessive, progressive multi-system disease that affects organ systems dependent on mitochondrial function that brings to neurological, cardiac, and metabolic dysfunction; Myotonic Dystrophy Type-1, a dominantly-inherited, monogenic progressive neuromuscular disease affecting skeletal muscle, heart, brain, and other organs; Fuchs Endothelial Corneal Dystrophy, a genetic eye disease characterized by bilateral degeneration of corneal endothelial cells and progressive loss of vision; and Huntington's Disease, a dominantly inherited, monogenic neurodegenerative disease characterized by movement, cognitive, and psychiatric disorders. Design Therapeutics, Inc. was incorporated in 2017 and is headquartered in Carlsbad, California.

Today's Range

Now: $3.76

$3.51

$3.79

50 Day Range

MA: $3.28

$2.48

$4.03

2 Week Range

Now: $3.76

$1.94

$8.47

Volume

217,668 shs

Average Volume

261,995 shs

Market Capitalization

$212.40 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.82

Jim Cramer’s “The Biggest Drug Ever”

From Behind the Markets | Ad